The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial
Open accessAbstract
BACKGROUND: For patients with heart failure, reduced left ventricular ejection fraction and iron deficiency, intravenous ferric carboxymaltose administration improves quality of life and exercise capacity in the short-term and reduces hospital admissions for heart failure up to 1 year. We aimed to evaluate the longer-term effects of intravenous ferric derisomaltose on cardiovascular events in patients with heart failure. METHODS: IRONMAN was a prospective, randomised, open-label, blinded-endpoint trial done at 70 hospitals in the UK. Patients aged 18 years or older with heart failure (left ventricular ejection fraction ≤45%) and transferrin saturation less than 20% or serum ferritin less than 100 μg/L were eligible. Participants were randomly assigned (1:1) using a web-based system to intravenous ferric derisomaltose or usual care, stratified by recruitment context and trial site. The trial was open label, with masked adjudication of the outcomes. Intravenous ferric derisomaltose dose was determined by patient bodyweight and haemoglobin concentration. The primary outcome was recurrent hospital admissions for heart failure and cardiovascular death, assessed in all validly randomly assigned patients. Safety was assessed in all patients assigned to ferric derisomaltose who received at least one infusion and all patients assigned to usual care. A COVID-19 sensitivity analysis censoring follow-up on Sept 30, 2020, was prespecified. IRONMAN is registered with ClinicalTrials.gov, NCT02642562. FINDINGS: Between Aug 25, 2016, and Oct 15, 2021, 1869 patients were screened for eligibility, of whom 1137 were randomly assigned to receive intravenous ferric derisomaltose (n=569) or usual care (n=568). Median follow-up was 2·7 years (IQR 1·8-3·6). 336 primary endpoints (22·4 per 100 patient-years) occurred in the ferric derisomaltose group and 411 (27·5 per 100 patient-years) occurred in the usual care group (rate ratio [RR] 0·82 [95% CI 0·66 to 1·02]; p=0·070). In the COVID-19 analysis, 210 primary endpoints (22·3 per 100 patient-years) occurred in the ferric derisomaltose group compared with 280 (29·3 per 100 patient-years) in the usual care group (RR 0·76 [95% CI 0·58 to 1·00]; p=0·047). No between-group differences in deaths or hospitalisations due to infections were observed. Fewer patients in the ferric derisomaltose group had cardiac serious adverse events (200 [36%]) than in the usual care group (243 [43%]; difference -7·00% [95% CI -12·69 to -1·32]; p=0·016). INTERPRETATION: For a broad range of patients with heart failure, reduced left ventricular ejection fraction and iron deficiency, intravenous ferric derisomaltose administration was associated with a lower risk of hospital admissions for heart failure and cardiovascular death, further supporting the benefit of iron repletion in this population. FUNDING: British Heart Foundation and Pharmacosmos.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab368 · Cited by 13,344
Self-citationHeidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Circulation · doi:10.1161/cir.0000000000001063 · Cited by 4,922
Ferric Carboxymaltose in Patients with Heart Failure and Iron Deficiency
Anker, S. D., Comin Colet, J., Filippatos, G., Willenheimer, R., Dickstein, K., Drexler, H., Lüscher, T. F., Bart, B., Banasiak, W., Niegowska, J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0908355 · Cited by 2,083 · cited 1×
“IRONMAN used a definition based on transferrin saturation, ferritin, or both—similar but not identical to the criteria used in most previous trials of intravenous iron in heart failure 4,5,10 that have been adopted by guidelines.”
MethodPonikowski, P., van Veldhuisen, D. J., Comin-Colet, J., Ertl, G., Komajda, M., Mareev, V., McDonagh, T., Parkhomenko, A., Tavazzi, L., Levesque, V., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehu385 · Cited by 1,242
Semiparametric regression for the mean and rate functions of recurrent events
Lin, D. Y., Wei, L. J., Yang, I., & Ying, Z. (2000) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/1467-9868.00259 · Cited by 969
Ponikowski, P., Kirwan, B.-A., Anker, S. D., McDonagh, T., Dorobantu, M., Drozdz, J., Fabien, V., Filippatos, G., Göhring, U. M., Keren, A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)32339-4 · Cited by 795
Self-citationIntravenous Iron in Patients Undergoing Maintenance Hemodialysis
Macdougall, I. C., White, C., Anker, S. D., Bhandari, S., Farrington, K., Kalra, P. A., McMurray, J. J. V., Murray, H., Tomson, C. R. V., Wheeler, D. C., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1810742 · Cited by 502
Self-citationLewis, G. D., Malhotra, R., Hernandez, A. F., McNulty, S. E., Smith, A., Felker, G. M., Tang, W. H. W., LaRue, S. J., Redfield, M. M., Semigran, M. J., et al. (2017) · JAMA · doi:10.1001/jama.2017.5427 · Cited by 480
Wolf, M., Rubin, J., Achebe, M., Econs, M. J., Peacock, M., Imel, E. A., Thomsen, L. L., Carpenter, T. O., Weber, T., Brandenburg, V., et al. (2020) · JAMA · doi:10.1001/jama.2019.22450 · Cited by 295
Nonparametric Analysis of Recurrent Events and Death
Ghosh, D., & Lin, D. Y. (2000) · Biometrics · doi:10.1111/j.0006-341x.2000.00554.x · Cited by 272
Cited by
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad195 · Cited by 2,612
Self-citationAuthors/Task Force Members:, McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., et al. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3024 · Cited by 466
Self-citationMaddox, T. M., Januzzi, J. L., Allen, L. A., Breathett, K., Brouse, S., Butler, J., Davis, L. L., Fonarow, G. C., Ibrahim, N. E., Lindenfeld, J., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.12.024 · Cited by 362
Gravel, J., D’Amours-Gravel, M., & Osmanlliu, E. (2023) · doi:10.1101/2023.03.16.23286914 · Cited by 220
Gravel, J., D’Amours-Gravel, M., & Osmanlliu, E. (2023) · Mayo Clinic Proceedings: Digital Health · doi:10.1016/j.mcpdig.2023.05.004 · Cited by 222
Metadata
- Authors
- Kalra, P. R., Cleland, J. G. F., Petrie, M. C., Thomson, E. A., Kalra, P. A., Squire, I. B., Ahmed, F. Z., Al-Mohammad, A., Cowburn, P. J., Foley, P. W. X., Graham, F. J., Japp, A. G., Lane, R. E., Lang, N. N., Ludman, A. J., Macdougall, I. C., Pellicori, P., Ray, R., Robertson, M., Seed, A., Ford, I., Kalra, P. R., Cleland, J. G., Petrie, M. C., Thomson, E. A., Kalra, P. A., Squire, I. B., Ahmed, F. Z., Al-Mohammad, A., Cowburn, P. J., Foley, P. W., Graham, F. J., Japp, A. G., Lane, R. E., Lang, N. N., Ludman, A. J., Macdougall, I. C., Pellicori, P., Ray, R., Robertson, M., Seed, A., Ford, I., Boon, N., Amoils, S., Chapman, C., Diness, T. G., McMurray, J., Mindham, R., Sandu, P., Strom, C. C., Travers, M., Wilcox, R., Struthers, A., Mark, P., Weir, C., Cowan, E., Turner, C., Austin, R., Rogers, P., Chandrasekaran, B., Fraile, E., Kyeremeh, L., McGregor, L., Osmanska, J., Meyer, B., Ahmad, F., Fisher, J., Summersgill, C., Adeniji, K., Chinnadurai, R., Massimo, L., Hardman, C., Sykes, D., Frank, S., Smith, S., Anwar, M., Whittington, B., Sookhoo, V., Lyons, S., Middle, J., Housley, K., Clark, A., Bulemfu, J., Critoph, C., Chong, V., Wood, S., Szwejkowski, B., Lang, C., Duff, J., MacDonald, S., Schiff, R., Donnelly, P., Nageh, T., Kunhunny, S., Gardner, R., McAdam, M., McPherson, E., Banerjee, P., Sear, E., Edwards, N., Glover, J., Murphy, C., Cooke, J., Spencer, C., Francis, M., Matthews, I., McKie, H., Marshall, A., Large, J., Stratford, J., Clifford, P., Boos, C., Keeling, P., Hughes, D., Wong, A., Jones, D., James, A., Williams, R., Leslie, S., Finlayson, J., Hannah, A., Campbell, P., Walsh, J., Quinn, J., Piper, S., Patale, S., Gupta, P., Sim, V., Knibbs, L., Lyons, K., Dixon, L., Petrie, C., Wong, Y.-K., Labinjoh, C., Duckett, S., Massey, I., Savage, H., Matias, S., Ramirez, J., Manisty, C., Hussain, I., Sankaranarayanan, R., Davis, G., McClure, S., Baxter, J., Wicks, E., Sobolewska, J., Murphy, J., Elzayat, A., Cooke, A., Wright, J., Williams, S., Muthumala, A., Chaggar, P., Webber, S., Ellis, G., Welch, M., Bulugahapitiya, S., Jackson, T., Pakrashi, T., Bakhai, A., Krishnamurthy, V., Gamma, R., Ellery, S., Jenkins, G., Thomas, G., Nightingale, A., Greenlaw, N., Wetherall, K., Clarke, R., Graham, C., Kean, S., Stevenson, A., Wilson, R., Boyle, S., McHugh, J., Hall, L., Woollard, J., Brunton, C., Dinnett, E., Reid, A., Howe, S., Nicholls, J., Cunnington, A., Douglas, E., Fegen, M., Jones, M., McGowan, S., Ross, B., Surtees, P., & Stuart, D.
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2022-12
- Volume
- 400
- Issue
- 10369
- Pages
- 2199-2209
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W4308249260
- Cited by
- 402
- References
- 24
- FWCI
- 52.44
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial. https://app.cochat.ai/papers/10.1016/s0140-6736(22)02083-9
- The paper
- Kalra, P. R., Cleland, J. G. F., Petrie, M. C., Thomson, E. A., Kalra, P. A., Squire, I. B., Ahmed, F. Z., Al-Mohammad, A., Cowburn, P. J., Foley, P. W. X., Graham, F. J., Japp, A. G., Lane, R. E., Lang, N. N., Ludman, A. J., Macdougall, I. C., Pellicori, P., Ray, R., Robertson, M., . . . Stuart, D. (2022). Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial. The Lancet. https://doi.org/10.1016/s0140-6736(22)02083-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.